AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival ...

Though most models aren’t ready for prime time, AI is expected to have a “tremendous” impact on practice in the coming years.

As life-extending technologies and aging interventions proliferate, questions surround who will be granted access to a longer ...

The U.S. Food and Drug Administration (FDA) announced a landmark decision on April 10, 2025, phasing out mandatory animal ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a ...

Discover how CRISPR gene editing is creating personalized cancer therapies, enhancing immunotherapy, and offering new hope ...